These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 31028202)
101. Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group. Mattavelli D; Wichmann G; Smussi D; Paderno A; Plana MS; Mesia RN; Compagnoni M; Medda A; Chiocca S; Calza S; Zhan Y; Rognoni C; Tarricone R; Stucchi E; Lorini L; Gurizzan C; Khelik K; Hovig E; Dietz A; Piazza C; Bossi P Front Oncol; 2024; 14():1433333. PubMed ID: 39165689 [TBL] [Abstract][Full Text] [Related]
102. Expression of p16INK4a, FLOT2, and EGFR in oropharyngeal carcinoma, prognostic significance and correlation with clinicopathological characteristics. Đokanović D; Gajanin R; Gojković Z; Klokić S; Sladojević I; Gajanin V; Reljić D; Jović-Đokanović O; Amidžić L; Marošević G Medicine (Baltimore); 2024 Aug; 103(33):e38894. PubMed ID: 39151502 [TBL] [Abstract][Full Text] [Related]
103. ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity. Chrysovergis A; Papanikolaou V; Mastronikolis N; Tsiambas E; Katsinis S; Manoli A; Papouliakos S; Ragos V; Pantos P; Peschos D; Mastronikolis S; Fotiades P; Mamoulidis P; Spyropoulou D; Kyrodimos E In Vivo; 2022; 36(3):1144-1149. PubMed ID: 35478149 [TBL] [Abstract][Full Text] [Related]
104. Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem. Falco M; Tammaro C; Takeuchi T; Cossu AM; Scafuro G; Zappavigna S; Itro A; Addeo R; Scrima M; Lombardi A; Ricciardiello F; Irace C; Caraglia M; Misso G Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406495 [TBL] [Abstract][Full Text] [Related]
109. Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: a series of 108 cases. Marioni G; Staffieri A; Bertolin A; Giacomelli L; D'Alessandro E; Ottaviano G; Accordi D; Stramare R; de Filippis C; Blandamura S Eur Arch Otorhinolaryngol; 2010 Jul; 267(7):1103-10. PubMed ID: 20052590 [TBL] [Abstract][Full Text] [Related]
110. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334 [TBL] [Abstract][Full Text] [Related]
111. Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. Ouyang X; Barling A; Lesch A; Tyner JW; Choonoo G; Zheng C; Jeng S; West TM; Clayburgh D; Courtneidge SA; McWeeney SK; Kulesz-Martin M Cancer Biol Ther; 2018; 19(10):921-933. PubMed ID: 29856687 [TBL] [Abstract][Full Text] [Related]
112. High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma. Jiang M; Zhang H; Xiao H; Zhang Z; Que D; Luo J; Li J; Mao B; Chen Y; Lan M; Wang G; Xiao H Oncol Lett; 2018 Jan; 15(1):931-939. PubMed ID: 29391895 [TBL] [Abstract][Full Text] [Related]